An interventional study of Transcatheter pulmonary valve implantation (TPVI) and VenusP-ValveTM System in Pulmonary Regurgitation, sponsored by Venus MedTech (HangZhou) Inc.. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Venus MedTech (HangZhou) Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pulmonary Valve Insufficiency with a site in United States — 2 open to participants now, 8 under way, none of them phase 3. Pulmonary Valve Insufficiency · United States.
Among the 15 studies in Pulmonary Valve Insufficiency with a site in United States, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 15th registered.
31 studies on the registry are indexed under Pulmonary Valve Insufficiency; 8 are open to participants now.
Browse Pulmonary Valve Insufficiency studies →2 of the 15 studies in Pulmonary Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Edwards Lifesciences · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Pulmonary Valve Insufficiency studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 60 is close to the median of 60 across 21 interventional studies indexed under Pulmonary Valve Insufficiency.
Median enrollment 75 across the 10 interventional studies, 140 across the 5 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 9 most frequent:
Venus MedTech (HangZhou) Inc. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Venus MedTech (HangZhou) Inc. has 2 studies filed under Pulmonary Valve Insufficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in Pulmonary Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05077774Medtronic CardiovascularHarmony TPV Post-Approval Study | 2026-11 |
| NCT02744677Edwards LifesciencesCOMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Pulmonary Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, multi-center, non-randomized interventional study to evaluate the safety and effectiveness of the VenusP-ValveTM System in patients with native right ventricular outflow tract (RVOT) dysfunction.
Post procedure, a clinical visit will be scheduled at pre-discharge, 30 days, 6 months, 12 months, and annually thereafter to 10 years.
About 60 subjects will be enrolled in this study. Data analysis will be performed after all enrolled subjects complete 6-month follow-up and the primary endpoint analysis report will be submitted to FDA for PMA approval.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Transcatheter pulmonary valve implantation (TPVI) · Device: VenusP-ValveTM System
A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.
VenusP-ValveTM System consists of two components: 1. Transcatheter Pulmonary Valve (TPV) 2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue. For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV. The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper.
The rate of procedure or device related mortality at the 30 days follow-up visit post procedure
Freedom from procedure or device related mortality at 30 days
Time frame: At 30 Days Post Procedure
The rate of re-intervention and acceptable hemodynamic function at 6 Month follow-up visit post procedure
Freedom from VenusP-Valve re-intervention and acceptable hemodynamic function at 6 months defined as: 1. No more than mild regurgitation measured by CMR; AND 2. Mean RVOT gradient as measured by echocardiography ≤35mmHg.
Time frame: At 6 Months Post Procedure
The rate of all-cause mortality, procedure or device related mortality, and procedure or device related Major Adverse Cardiac and Cerebrovascular Events (MACCE) out to 10 years
1. Freedom from all-cause mortality, procedure or device related mortality out to 10 years 2. Freedom from procedure or device related Major Adverse Cardiac and Cerebrovascular Events (MACCE) out to 10 years 3. MACCE is defined as a non-hierarchic composite including the following procedure or device related events: 1) Stroke 2) RVOT reintervention 3) Arrhythmia 4) Coronary artery compression requiring intervention or causing myocardial infarction 5) Device-related endocarditis 6) Major stent fracture 7) Valve thrombosis 8) Valve embolization or significant malposition 9) Major vascular or access complications\* 10) Pulmonary embolism
Time frame: Through Ten Years Post Procedure
The rate of technical Success during the procedure
Technical success at exit from catheterization lab or operating room Defined as a composite of: 1. Freedom from procedure or device related mortality 2. Successful access, delivery of the device, and retrieval of the delivery system 3. Correct positioning of the valve(s) into the proper anatomical location 4. Freedom from reintervention related to the device or to a major vascular or access-related, or cardiac structural complications
Time frame: During the Procedure
The rate of acceptable hemodynamic performance at 30 days, 1-5 years, 7 years and 10 years.
Acceptable hemodynamic performance at 30 days, 1-5 years, 7 years and 10 years. Defined as: 1. Mean RVOT gradient ≤ 35mmHg AND, 2. No more than mild regurgitation measured by echocardiography
Time frame: At 30 Days, 1-5 Years, 7 Years and 10 Years Post Procedure
The rate of procedure success out to 30 days
Procedure success out to 30 days, defined as follows: 1. Device success at 30 days. Defined as a composite of: * Freedom from procedure or device related mortality * Original intended device in place * No additional surgical or interventional procedures related to the procedure or the device since completion of the index procedure * Hemodynamic performance: relief of insufficiency (mild or less pulmonary regurgitation) without producing the opposite (mean RVOT gradient \> 35 mmHg) as measured by echocardiography * No new ventricular arrhythmia requiring ICD implantation 2. None of the following procedure or device related serious adverse events: * Life-threatening major bleeding * Major vascular or cardiac structural complications requiring unplanned reintervention or surgery * Stage 2 or 3 acute kidney injury (AKI) includes new dialysis * Pulmonary embolism * Severe heart failure or hypotension requiring intravenous inotrope
Time frame: At 30 Days Post Procedure
The rate of valve dysfunction out to 10 years
Freedom from valve dysfunction out to 10 years Defined as a composite of: 1. RVOT re-intervention for device-related reasons 2. Hemodynamic dysfunction of the valve (moderate or greater pulmonary regurgitation, and/or a mean RVOT gradient \> 35 mmHg)
Time frame: Through Ten Years Post Procedure
New York Heart Association (NYHA) classification Through out to 10 years
Functional status (New York Heart Association (NYHA) classification) out to 10 years
Time frame: Through Ten Years Post Procedure
Characterization of quality-of-life scores out to 5 year, and at 10 years
Characterization of quality-of-life scores out to 5 year, and at 10 years As assessed by the SF-36-QOL.
Time frame: Through Five Years Post Procedure, and at 10 Years Post Procedure
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Jun 2026, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Valve Insufficiency →
Venus MedTech (HangZhou) Inc.